Trials / Completed
CompletedNCT01854814
The Effects of Mycophenolate Mofetil (MMF) on Renal Outcomes in Advanced Immunoglobulin A (IgA) Nephropathy Patients
The Effects of Mycophenolate Mofetil on Renal Outcomes in Patients With Advanced IgA Nephropathy: a Randomized Open-label Study
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 238 (actual)
- Sponsor
- Fan Fan Hou · Academic / Other
- Sex
- All
- Age
- 16 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The study is to evaluate the effect of Mycophenolate Mofetil compared with losartan alone on time to doubling of serum creatinine or the onset of end stage renal disease in patients with advanced IgA nephropathy who are treated with the maximal tolerated daily dose of losartan.The study will also assess the effects of MMF compared with losartan alone on the changes of urine albumin excretion and the changes in estimated glomerular filtration rate.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Mycophenolate mofetil | Mycophenolate mofetil 1.5g/day plus maximum tolerated labeled dose losartan |
| DRUG | Losartan | Maximum tolerated labeled dose of Losartan |
Timeline
- Start date
- 2013-07-01
- Primary completion
- 2022-02-01
- Completion
- 2022-05-01
- First posted
- 2013-05-16
- Last updated
- 2022-07-11
Locations
3 sites across 1 country: China
Source: ClinicalTrials.gov record NCT01854814. Inclusion in this directory is not an endorsement.